New hope for advanced cancers: experimental drug NUV-1511 enters human trials

NCT ID NCT06334432

Ongoing Disease control Sponsor: Nuvation Bio Inc. Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 16 times

Summary

This study tests a new drug called NUV-1511 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors. The study includes people with certain breast, prostate, pancreatic, and ovarian cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Carolina BioOncology Institute

Huntersville, North Carolina, 28078, United States
Fred Hutchinson

Seattle, Washington, 98109, United States
Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Karmanos Cancer Center

Detroit, Michigan, 48201, United States
Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
NEXT Oncology

Irving, Texas, 75038, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
START Mountain

Salt Lake City, Utah, 84124, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR HER2-NEGATIVE BREAST CANCER METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PANCREATIC CANCER PLATINUM-RESISTANT OVARIAN CANCER (PROC)